Sunshine Biopharma, Inc. (SBFMW)
| Market Cap | 4.46M -13.0% |
| Revenue (ttm) | 35.35M +4.1% |
| Net Income | -5.83M |
| EPS | -8.20 |
| Shares Out | 3.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | 0.0160 - 0.6498 |
| Beta | 1.31 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About SBFMW
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurin... [Read more]
News
Sunshine Biopharma files to sell 24.48M shares of common stock
16:19 EDT Sunshine Biopharma (SBFM) files to sell 24.48M shares of common stock
Sunshine Biopharma provides update, outlines plans for oncology project
Sunshine Biopharma (SBFM) provided an update and outlined next plans for its oncology project, the K1.1 mRNA lipid nanoparticle program. The gene encoding the K1.1 mRNA is a tumor suppressor…
Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer
K1.1 mRNA demonstrated tumor-suppressing activity as a single agent in multiple in vivo hepatocellular carcinoma models Program targets a tumor suppressor frequently mutated in difficult-to-treat lung...
Sunshine Biopharma receives Canadian regulatory approval for Enalapril
Sunshine Biopharma (SBFM) announces the approval of its generic Enalapril tablets 2.5mg, 5mg, 10mg and 20mg for the Canadian market. Enalapril is the generic equivalent of the brand name, Vasotec.
Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market
Global anti-hypertensive drug market projected to reach $37.24 billion by 2034 Enalapril is a widely prescribed ACE inhibitor used to treat hypertension, heart failure and left ventricular dysfunction...
Sunshine Biopharma launches generic amoxicillin formulation in Canada
Sunshine Biopharma (SBFM) announced the launch of its generic Amoxicillin formulation in the Canadian market. Sunshine Biopharma’s generic version will be available in multiple dosages and strengths, ...
Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market
Sunshine Biopharma's Amoxicillin now shipping to Canadian pharmacies in multiple dosages and strengths Launch expands Sunshine Biopharma's growing portfolio of essential prescription medications Globa...
Sunshine announces approval of generic Dienogest tablets for Canadian market
Sunshine Biopharma (SBFM) announce the approval of its generic Dienogest tablets of 2mg for the Canadian market. Dienogest is the generic equivalent of the brand name, Visanne Dienogest works through…
Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval
Dienogest is first-line therapy for pelvic pain associate with endometriosis The endometriosis treatment market is projected to reach $5.2 billion by 2034 FORT LAUDERDALE, FL / ACCESS Newswire / Augus...
Sunshine Biopharma announces approval of generic Ondansetron tablets
Sunshine Biopharma (SBFM) announces the approval of its generic Ondansetron tablets of 4mg and 8mg for the Canadian market. Ondansetron is the generic equivalent of the brand name, Zofran. Sunshine…
Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting
FORT LAUDERDALE, FL / ACCESS Newswire / July 28, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medic...
Sunshine Biopharma announces publication of new results on MR1-114
Sunshine Biopharma (SBFM) announced the publication of new research results in the Journal of Medicinal Chemistry. The published data demonstrate a novel PLpro inhibitor, MR1-114, with nanomolar poten...
Sunshine Biopharma and University of Arizona Publish Significant New Research Findings
FORT LAUDERDALE, FL / ACCESS Newswire / July 20, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medic...
Sunshine Biopharma receives Canadian approval for generic Arimidex
Sunshine Biopharma (SBFM) announced the approval of its generic Anastrozole tablets of 1mg for the Canadian market. Anastrozole is the generic equivalent of the brand name breast cancer drug, Arimidex...
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R)
FORT LAUDERDALE, FL / ACCESS Newswire / June 25, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medic...
Sunshine Biopharma announces Canadian approval for Rivaroxaban
Sunshine Biopharma (SBFM) announces the approval of its generic Rivaroxaban tablets of 2.5mg, 10mg, 15mg and 20mg for the Canadian market. Rivaroxaban is the generic equivalent of the brand name…
Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)
FORT LAUDERDALE, FL / ACCESS Newswire / June 1, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medica...
Sunshine Biopharma Inc trading halted, news pending
19:50 EDT Sunshine Biopharma (SBFM) Inc trading halted, news pending
Sunshine Biopharma issued U.S. patent for coronavirus treatment tech
Sunshine Biopharma (SBFM) announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,624,066 B2, titled “Compounds and Methods for Treatment of Coronavirus Infection.” ...
Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology
FORT LAUDERDALE, FL / ACCESS Newswire / May 29, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medica...
Sunshine Biopharma announces 1-for-10 reverse split of its common stock
Sunshine Biopharma (SBFM) announced a one for ten reverse split of its common stock, effective at market open on June 1, 2026. The reverse stock split was undertaken to regain…
Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
FORT LAUDERDALE, FL / ACCESS Newswire / May 28, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medica...
Sunshine announces approval of generic amoxicillin formulation for Canada
Sunshine Biopharma (SBFM) announces the approval of its generic Amoxicillin formulation for the Canadian market. “This strategic expansion reinforces Sunshine Biopharma’s commitment to providing affor...
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin
FORT LAUDERDALE, FL / ACCESS Newswire / May 21, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medica...
3 Penny Stocks to Watch Now, 5/19/26
GeoVax Labs ($GOVX), Roboai ($AIIO), and Sunshine Biopharma ($SBFM) are the three penny stocks to watch on May 19, according to TipRanks’ Penny Stock Screener tool. Penny stocks refer to…